Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396463 | 1.00 | CYP2A6 (1.00) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL15842646 | 0.82 | CYP2A6 (0.70) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL15306019 | 0.82 | CYP2A6 (0.72) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL16283608 | 0.81 | CYP2A6 (0.68) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL11036109 | 0.81 | CYP2A6 (1.00) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL15842640 | 0.81 | CYP2A6 (0.68) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL16283607 | 0.80 | CYP2A6 (0.66) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL1627582 | 0.78 | CYP2A6 (0.64) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL15842925 | 0.77 | KCNA3 (0.67) | CYP2A6CYP3A4KDM4EALDH1A1GLA | |
| SCHEMBL15842533 | 0.77 | CYP2A6 (0.66) | CYP2A6CYP3A4KDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110168030-A | Thermoformable and scratch-resistant photopolymer coating | 上阿尔萨斯大学 | 2019-08-23 | — | — | CN | claimed |
| EP-3526297-A1 | THERMOFORMABLE AND SCRATCH-RESISTANT PHOTOPOLYMER COATINGS | Université de Haute Alsace (FR) | 2019-08-21 | — | — | EP | claimed |
| EP-3320002-B1 | POLYMERIZATION SYSTEM USING DOUBLE CLICK MICHAEL ADDITION AND PHOTOPOLYMERIZATION | UNIV HAUTE ALSACE (FR) | 2019-05-01 | — | — | EP | claimed |
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | claimed |
| US-12138232-B2 | Compounds for treating coronavirus infection | NLC PHARMA LTD (IL) | 2024-11-12 | — | — | US | disclosed |
| US-20240130983-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | NLC PHARMA LTD (IL) | 2024-04-25 | — | — | US | disclosed |
| US-11857517-B2 | Compounds for treating corona virus infection | NLC PHARMA LTD (IL) | 2024-01-02 | — | — | US | disclosed |
| CN-115916172-A | Compounds for treating coronavirus infections | NLC制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4103164-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | NLC Pharma Ltd (IL) | 2022-12-21 | — | — | EP | disclosed |
| US-20220387354-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | NLC PHARMA LTD (IL) | 2022-12-08 | — | — | US | disclosed |
| CN-111848451-B | Preparation method of cyano compound | 中国科学院化学研究所 | 2021-08-24 | — | — | CN | disclosed |
| EP-0942911-B1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LAB (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6046207-A | FOR INHIBITING ALPHA-1 ADRENORECEPTORS AND TREATING BENIGN PROSTATIC HYPERPLASIA, ALSO CALLED BENIGN PROSTATIC HYPERTROPHY, OR OTHER UROLOGICAL OR GYNECOLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION, NEUROGENIC BLADDER | ABBOTT LABORATORIES | 2000-04-04 | — | — | US | disclosed |
| CN-1246861-A | Benzopyranopyrrole and benzopyranopyridine alpha-1 adrenergic compounds | ABBOTT LAB (US) | 2000-03-08 | — | — | CN | disclosed |
| EP-0942911-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | Abbott Laboratories (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5891882-A | TREATING BENIGN PROSTATIC HYPERPLASIA OR OTHER UROLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION AND NEUROGENIC BLADDER, OR GYNECOLOGICAL SYNDROMES SUCH AS DYSMENORRHEA | ABBOTT LABORATORIES (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998024791-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-06-11 | — | — | WO | disclosed |
| CN-1069272-A | The method for preparing benzo pyrrole or thiapyran and pyrazoles | BOOTS CO PLC (GB) | 1993-02-24 | — | — | CN | disclosed |
| US-4441969-A | ARYL HYDROXY CARBOXYLIC ACID | OMI INTERNATIONAL CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240130983-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | SARS1, BECN1, PRSS1 | CYP2A6 647/4885CYP3A4 346/4885KDM4E 2940/4885 |
| US-11857517-B2 | Compounds for treating corona virus infection | SARS1, CTSA, CTSV | CYP2A6 431/4885CYP3A4 525/4885KDM4E 2632/4885 |
| US-20220387354-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | SARS1, BECN1, PRSS1 | CYP2A6 647/4885CYP3A4 346/4885KDM4E 2940/4885 |
| US-12138232-B2 | Compounds for treating coronavirus infection | SARS1, BECN1, PRSS1 | CYP2A6 647/4885CYP3A4 346/4885KDM4E 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.